Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer's disease transgenic mice
Open Access
- 17 December 2013
- journal article
- Published by Wiley in Aging Cell
- Vol. 13 (2), 379-390
- https://doi.org/10.1111/acel.12185
Abstract
Alzheimer’s disease (AD) is the most common type of dementia. It is the only one of the top ten causes of death in the USA for which prevention strategies have not been developed. Although AD has traditionally been associated with the deposition of amyloid β plaques and tau tangles, it is becoming increasingly clear that it involves disruptions in multiple cellular systems. Therefore, it is unlikely that hitting a single target will result in significant benefits to patients with AD. An alternative approach is to identify molecules that have multiple biological activities that are relevant to the disease. Fisetin is a small, orally active molecule which can act on many of the target pathways implicated in AD. We show here that oral administration of fisetin to APPswe/PS1dE9 double transgenic AD mice from 3 to 12 months of age prevents the development of learning and memory deficits. This correlates with an increase in ERK phosphorylation along with a decrease in protein carbonylation, a marker of oxidative stress. Importantly, fisetin also reduces the levels of the cyclin-dependent kinase 5 (Cdk5) activator p35 cleavage product, p25, in both control and AD brains. Elevated levels of p25 relative to p35 cause dysregulation of Cdk5 activity leading to neuroinflammation and neurodegeneration. These fisetin-dependent changes correlate with additional anti-inflammatory effects, including alterations in global eicosanoid synthesis, and the maintenance of markers of synaptic function in the AD mice. Together, these results suggest that fisetin may provide a new approach to the treatment of AD.Keywords
Funding Information
- Alzheimer's Association (IRG-07-58874)
- National Institutes of Health (R21 NS077201)
This publication has 48 references indexed in Scilit:
- Eicosanoids in Metabolic SyndromeAdvances in pharmacology, 2013
- A Novel Neurotrophic Drug for Cognitive Enhancement and Alzheimer's DiseasePLOS ONE, 2011
- The Extracellular Signal-regulated Kinase Mitogen-activated Protein Kinase/Ribosomal S6 Protein Kinase 1 Cascade Phosphorylates cAMP Response Element-binding Protein to Induce MUC5B Gene Expression via d-Prostanoid Receptor SignalingJournal of Biological Chemistry, 2011
- Altered neuroinflammatory, arachidonic acid cascade and synaptic markers in postmortem Alzheimer’s disease brainTranslational Psychiatry, 2011
- Systemic and Central Immunity in Alzheimer's Disease: Therapeutic ImplicationsCNS Neuroscience & Therapeutics, 2011
- Impact of the CD40-CD40L Dyad in Alzheimers DiseaseCNS & Neurological Disorders - Drug Targets, 2010
- Flavonoid intake and disability-adjusted life years due to Alzheimer’s and related dementias: a population-based study involving twenty-three developed countriesPublic Health Nutrition, 2010
- The Anti-Inflammatory Effects of ProstaglandinsJournal of Investigative Medicine, 2009
- Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse modelsFree Radical Biology & Medicine, 2008
- Co-expression of multiple transgenes in mouse CNS: a comparison of strategiesBiomolecular Engineering, 2001